FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P. Angus, Gary L. Johnson, Gaurav Mehta et al.|npj Breast Cancer|2021Cited by 24
Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibitionEvan S. Dubose, Steven P. Angus|Frontiers in Oncology|2024Cited by 7